ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,495Medicare Part D Prescriptions Filled, Including Refills

Rank: 184 out of 1111

$519K Total Retail Price of All Prescriptions

Rank: 207 out of 1111

439 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oklahoma
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 439 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

21% of this provider’s 439 patients filled at least one prescription for a schedule three drug, compared to an average of 18%.

Risky Drugs to Seniors

3% of this provider’s 7,949 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oklahoma
LISINOPRIL 421 385 1 2
HYDROCODONE-ACETAMINOPHEN 400 235 S3 2 1
OMEPRAZOLE 381 339 3 4
LOVASTATIN 266 230 4 41
SIMVASTATIN 257 238 5 5
LEVOTHYROXINE SODIUM 254 235 6 3
HYDROCHLOROTHIAZIDE 248 243 7 11
METFORMIN HCL 222 156 8 8
AMLODIPINE BESYLATE 216 207 9 7
FUROSEMIDE 211 179 10 6
ZOLPIDEM TARTRATE 200 174 11 16
ATENOLOL 178 153 12 22
METOPROLOL TARTRATE 150 129 13 12
ATORVASTATIN CALCIUM 142 129 14 15
WARFARIN SODIUM 140 133 15 19
GABAPENTIN 132 110 16 10
SERTRALINE HCL 115 97 17 24
METFORMIN HCL ER 115 102 17 84
TRAMADOL HCL 111 100 19 13
PANTOPRAZOLE SODIUM 105 101 20 50
BENAZEPRIL HCL 102 85 21 97
CRESTOR 101 91 22 33
MELOXICAM 96 83 23 18
CITALOPRAM HBR 94 80 24 14
GLIPIZIDE 91 74 25 57
PRAVASTATIN SODIUM 91 89 25 17
TRAZODONE HCL 88 80 27 32
FLUTICASONE PROPIONATE 88 72 27 27
SPIRONOLACTONE 88 69 27 83
TAMSULOSIN HCL 87 87 30 28
CARVEDILOL 86 69 31 21
METOPROLOL SUCCINATE 84 84 32 20
ADVAIR DISKUS 82 62 33 43
POTASSIUM CHLORIDE 82 75 33 9
DIOVAN 78 73 35 51
PREDNISONE 70 58 36 48
DOXAZOSIN MESYLATE 69 67 37 87
ESTRADIOL 66 62 R 38 102
IPRATROPIUM BROMIDE 65 60 39 296
LISINOPRIL-HYDROCHLOROTHIAZIDE 65 53 39 23
DIGOXIN 61 55 41 47
PLAVIX 60 58 42 49
FLUOXETINE HCL 59 50 43 44
PROMETHAZINE HCL 56 19 R 44 69
AMITRIPTYLINE HCL 56 49 R 44 64
LOSARTAN POTASSIUM 56 53 44 34
PROAIR HFA 54 35 47 38
SPIRIVA 54 43 47 53
CLOPIDOGREL 54 47 47 30
CYCLOBENZAPRINE HCL 52 0 R 50 37
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 6, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.